Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

[1]  R. Paridaens,et al.  Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Perez,et al.  Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Michalaki,et al.  Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Letrozole or Anastrozole. A Phase II Trial Conducted by the Hellenic Group of Oncology (HELGO) , 2006, Tumori.

[4]  L. Mauriac,et al.  Compassionate use of fulvestrant: Experience from the Institut Bergonie , 2005 .

[5]  A. Lluch,et al.  Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. , 2005, Cancer treatment reviews.

[6]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  O. Přibylová,et al.  Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy-updated results from an expanded access programme , 2004 .

[8]  L. Parker,et al.  Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer , 2004, Clinical pharmacokinetics.

[9]  M. Ellis,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.

[10]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Dowsett,et al.  Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer , 2001 .

[13]  M. Dowsett,et al.  Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. , 2001, Cancer research.

[14]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Lønning,et al.  Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Wakeling,et al.  Similarities and distinctions in the mode of action of different classes of antioestrogens. , 2000, Endocrine-related cancer.

[17]  A. Wakeling,et al.  Use of pure antioestrogens to elucidate the mode of action of oestrogens. , 1995, Biochemical pharmacology.

[18]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.